Compare LEE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | CTMX |
|---|---|---|
| Founded | 1890 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | LEE | CTMX |
|---|---|---|
| Price | $4.51 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 84.4K | ★ 2.8M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $562,341,000.00 | $113,631,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.74 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $0.40 |
| 52 Week High | $15.15 | $4.66 |
| Indicator | LEE | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 54.87 |
| Support Level | $3.58 | $4.07 |
| Resistance Level | $5.72 | $4.48 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 52.52 | 45.96 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.